Direkt zum Inhalt
Merck

Silver nitrate prophylaxis.

Canadian Medical Association journal (1984-08-01)
G Schneider
ZUSAMMENFASSUNG

In many countries the statutory use of silver nitrate prophylaxis as soon as possible after birth has recently been reviewed from both a human rights and a medical standpoint. It has been argued that silver nitrate does not prevent all cases of gonococcal ophthalmia neonatorum (GON) and that it causes chemical conjunctivitis, pain and visual impairment, which may interfere with parent-infant bonding. Furthermore, the low incidence of GON, better methods of prenatal diagnosis, and the availability of suitable alternative prophylactic medication and of effective methods of treatment of GON have prompted recommendations that alternative prophylaxis be legally allowed or that mandatory prophylaxis be eliminated altogether. This paper reviews the situation and provides updated recommendations.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Silbernitrat, ACS reagent, ≥99.0%
Sigma-Aldrich
Silbernitrat, ReagentPlus®, ≥99.0% (titration)
Sigma-Aldrich
Silbernitrat, 99.9999% trace metals basis
Sigma-Aldrich
Silbernitrat auf Kieselgel, extent of labeling: ~10 wt. % loading, +230 mesh
Sigma-Aldrich
Silbernitrat -Lösung, 2.5 % (w/v) AgNO3 in H2O
Sigma-Aldrich
Silbernitrat, BioReagent, suitable for plant cell culture, >99% (titration)
Sigma-Aldrich
Silbernitrat, BioXtra, >99% (titration)
Sigma-Aldrich
Silbernitrat, tested according to Ph. Eur.